Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI）
osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID
27959700), but acquired drug resistance will occur. Previous studies show that apoptosis
escape can lead to EGFR-TKI resistance.Osimertinib resistant cells show abnormal activation
of PI3K/AKT/BIM activation(PMID 28765329). The classical drug aspirin can effectively
decrease AKT phosphorylation and activate of BIM(PMID 28881293).So Investigators speculate
that aspirin may decrease the PI3K/AKT/BIM signaling pathways, then promote osimertinib
resistant cells apoptosis. The current study aims to evaluate the combination of aspirin and
osimertinib in patients with EGFR/T790M mutations.
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University